Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. lifted its position in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 72.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 993,743 shares of the company’s stock after buying an additional 417,400 shares during the period. Bicycle Therapeutics accounts for approximately 20.0% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 3rd largest holding. Tybourne Capital Management HK Ltd. owned approximately 1.44% of Bicycle Therapeutics worth $6,907,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Acadian Asset Management LLC purchased a new position in shares of Bicycle Therapeutics during the first quarter valued at approximately $1,065,000. Janney Montgomery Scott LLC purchased a new position in shares of Bicycle Therapeutics during the second quarter valued at approximately $697,000. Principal Financial Group Inc. lifted its stake in shares of Bicycle Therapeutics by 55.3% during the first quarter. Principal Financial Group Inc. now owns 631,260 shares of the company’s stock valued at $5,359,000 after buying an additional 224,790 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Bicycle Therapeutics during the first quarter valued at approximately $214,000. Finally, Westfield Capital Management Co. LP increased its position in Bicycle Therapeutics by 1.8% during the first quarter. Westfield Capital Management Co. LP now owns 2,657,305 shares of the company’s stock worth $22,561,000 after purchasing an additional 46,968 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Ratings Changes

BCYC has been the subject of several research analyst reports. Morgan Stanley dropped their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 price target on shares of Bicycle Therapeutics and gave the stock an “outperform” rating in a research report on Monday, August 11th. JMP Securities dropped their price target on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicycle Therapeutics in a research report on Tuesday, October 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $44.00 price target (down previously from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.22.

Insider Activity

In other news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares of the company’s stock, valued at $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 8,527 shares of company stock valued at $71,738 over the last ninety days. 8.50% of the stock is owned by corporate insiders.

Bicycle Therapeutics Stock Up 0.9%

Bicycle Therapeutics stock opened at $7.88 on Monday. Bicycle Therapeutics PLC Sponsored ADR has a 52-week low of $6.10 and a 52-week high of $25.77. The firm has a fifty day moving average of $7.55 and a 200-day moving average of $7.83. The firm has a market capitalization of $546.16 million, a P/E ratio of -2.25 and a beta of 1.47.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The business had revenue of $2.90 million during the quarter, compared to analyst estimates of $9.43 million. On average, research analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.